Partners To Avaya: Be Clear On Radvision Integration, Channel Sales Plans

Avaya and Radvision partners see positives in Avaya's planned $230 million acquisition of videoconferencing specialist Radvision, but are cautioning Avaya to make clear to partners right away how they expect those video products to be sold through channel partners.

Avaya confirmed the $230 million acquisition Thursday: a pickup that gives Avaya an in-house option for video endpoints and infrastructure to complement its unified communications dominance and be a fully integrated part of its Aura UC platform, instead of relying on third-party OEM or strategic video partnerships.

The deal bolsters Avaya's ability to compete with Cisco, Polycom and LifeSize Communications in the enterprise videoconferencing space -- even if it means dumping partner agreements with Polycom and LifeSize down the line.

It's a statement move by Avaya, most solution providers agreed, especially as Avaya heads for an initial public offering. And it's especially good for Radvision, which has struggled to recover from the loss of a lucrative OEM agreement with Cisco two years ago.

"Avaya had been dabbling in video and not really committed to it," said Mike Brandofino, executive vice president, video and communications for Tampa-based solution provider AVI-SPL. "They had the LifeSize OEM and the Polycom resell relationship, but to go head-to-head against Cisco and Polycom, if you don't have a complete solution that's yours, you're at a disadvantage. So it's good for Avaya. And for Radvision, they needed to find a home after they were used and then kicked to the curb by Cisco. It's a great technology and a great platform."

[Related: Where's The Puck Going In Enterprise Videoconferencing? ]

AVI-SPL, ranked No. 48 on CRN's 2011 VAR500 listing and one of the country's top video integrators, has been a Radvision partner for two years, and doesn't resell Avaya PBX products but has been brought in to support Avaya in deals where video integration work was required, Brandofino said.

When Cisco acquired Tandberg in 2010, it too readily opened up Tandberg video products to UC and data networking-focused Cisco partners that didn't have video backgrounds, Brandofino said, and also had a host of initial problems with distribution of the products.

The same thing could happen at Avaya, Brandofino warned.

"Cisco kind of messed up that distribution in the beginning by allowing folks who didn't really sell video to sell it," Brandofino said. "Avaya is a whole lot of audio and voice integrators that don't know know a lot about video. It will be interesting to see how they get those folks up to speed. I hope they set the bar for the people allowed to sell that technology high."

Brandofino urged Avaya not to ignore Radvision's channel partners and use the input of those partners to determine how it will certify partners to sell Radvision video.

"I'd much rather see us partnering with Avaya resellers," he said. "We don't sell your audio stuff, but if you have video opportunities, bring us in, and we'll do it, especially if it's a managed services component. It'll be a while before Avaya resellers are able to do that on their own, so Avaya should foster relationships with the prior [Radvision] reseller channel and make sure they keep that expertise."

Avaya needs to come up with a clear plan and communicate that as soon as possible to partners, VARs said.

"The key is Avaya's ability to integrate and get the playbooks and support structure out to the partners as soon as possible," said Ed Wadbrook, vice president, applications and collaborative solutions for Carousel Industries, an Exeter, R.I.-based solution provider and one of Avaya's top national partners.

Wadbrook said Radvision brings a number of strong products to Avaya's portfolio and would also be fit for Avaya's expanded efforts around DevConnect, Avaya's program for third party app developer partners. Radvision's holdings include BEEHD, a suite of voice and video developer tools.

"What they get is room systems, telepresence, Radvision's Scopia [line] -- which includes a pretty dynamic mobile client -- and a good development environment, which goes with what Avaya's been doing with DevConnect," said Wadbrook, a former director of Avaya's Aura product group and a longtime UC executive. "It's not dissimilar to what Cisco has done in terms of pulling together more of the video assets. What Radvision has is a scalable video coding (SVC) technology that offers a more advanced approach to videoconferencing and a more judicious use of bandwidth."

Next: Was Avaya's Move A 'Knee Jerk' Reaction?

Carousel is well positioned to expand its videoconferencing business behind Avaya's move, Wadbrook said. The solution provider also partners with Polycom and other video players like Vidyo, and has been building its video practice throughout the past two years, including via a 2011 acquisition of A/V integrator OmniPresence.

"Carousel has been doing this for many years and doing it with a multi-vendor approach," Wadbrook said. "We understand the specific needs of this space and can add it to the portfolio we already have, which is unique in the community of Avaya channel partners."

Wadbrook and several partners cited the breadth of Radvision's portfolio and its emphasis on mobile video through the Scopia Mobile application as attractive to partners wrestling with customers' BYOD challenges.

"It's a real positive in that it now allows Avaya the ability to provide customers with a suite of cost effective, easy-to-use, high definition video collaboration solutions to further build out the UC portfolio," said Richard Tarity, executive vice president, sales and marketing for Transcend United, a Wayne, Pa.-based solution provider. "With that ever demanding and ever-changing BYOD market, Radvision integration into the Avaya product line is a home run."

Other Avaya partners say they'll need Avaya to be as up front as possible about how Radvision will benefit its channel and how it intends for partners to sell its associated video wares.

"It seems like a knee-jerk reaction," said Stuart Chandler, president and CEO of Optivor Technologies, an Annapolis Junction, Md.-based solution provider and top Avaya data networking partner. "They want to get further into video because Cisco had its video play, and LifeSize went to Logitech."

Chandler said he hadn't seen communication from Avaya about Radvision channel plans and that partners would need a clearly-defined strategy soon.

"The big thing for me back in the Nortel days was that information got out, and everyone was clear about strategy, and you had calls with customers and the partner community was behind it, being told why it was going to work," Chandler said. "Avaya seems to be making a lot of moves because it needs to IPO and is trying to hit quarterly numbers. They're doing things that aren't clear and defy their channel strategy. People want to hear from Avaya that it's supportive of partners and that this is important for partners."

Next: Avaya Talks Partners, Radvision Particulars

Avaya acquired Radvision for its strong technology that's complementary to Avaya's unified communications portfolio and SIP architecture, for a strong engineering group and talent pool, to have a fully integrated video solution at Avaya and to bring video intellectual property in-house so it can innovate faster, said Hugh McCullen, Avaya senior director for business development and strategic alliances.

"Video isn't just a CIO conversation, it's an end-user conversation," McCullen said. "Whether it's H.R., or finance, or the sales organization, you often have different video and applications touch points that you have to force-fit together. They're begging for a native video solution. We can natively integrate this intellectual property into the Avaya portfolio and drive seamless interoperability to promote and support BYOD."

"The important thing to note is that these endpoints and infrastructure will interoperate with Avaya on day one," said Nick Francis, Avaya's vice president of sales and marketing, video collaboration. "We'll have a full solution to sell -- a solution that will be tightly interoperable with our UC products and our data networking products -- at the beginning."

Avaya expects the acquisition to close within 90 days, and the plan right now is to keep Radvision intact -- including engineers and executive team -- and run Radvision as a business unit of Avaya focused on videoconferencing. Targeted sales teams from the combined Avaya and Radvision sales staff will attack the market, Francis said.

"But we don't want to encumber a smaller company while it's being assimilated," he said.

Avaya will provide more details on channel integration as the acquisition closes, Francis said, but will be deliberate about how it offers the Radvision products to its channel as well as how it addresses Radvision's existing partners, including the handful of solution providers Radvision has in North America.

"We are not going to require Radvision partners to become Avaya partners," Francis said. "We'll invest in the partners Radvision has and add to them our own set of partners, but it's not going to be something where we place a whole lot of demands on those partners."

Radvision represents Avaya's biggest acquisition since it bought Nortel's former enterprise unit in 2009, though the scope of the product and channel integration isn't nearly as large. It has made several small acquisitions since then, but Radvision's video footprint gives it a substantial videoconferencing boost that partners want to make sure they're a key part of.

"Don't ignore the channel," AVI-SPL's Brandofino said. "I think Cisco and Polycom both learned the hard way that it can hurt sales when the partners aren't on board with what you're doing. Avaya can reach out to us and get our viewpoints on the good and bad of what happened with Cisco, and learn from those mistakes. Keep us in the loop."

New study finds intermittent fasting could help weight loss, hypertension and mood

Watch CBS News

A new study published in the JAMA Internal Medicine found eating only between the hours of 7 a.m. and 3 p.m. could help people lose weight and treat hypertension. Good Housekeeping's deputy nutrition director and registered dietician Stefani Sassos joins "CBS Mornings" to discuss the study's findings and limitations.

Be the first to know

Get browser notifications for breaking news, live events, and exclusive reporting.

Ozempic could help curb alcohol abuse, study reveals

The latest weight loss craze could also help people control their drinking.

Semaglutide treatments such as Ozempic and Wegovy have been shown to reduce the symptoms of alcohol use disorder (AUD), according to a study published in The Journal of Clinical Psychiatry on Nov. 27.

The collaborative study from The University of Oklahoma (OU) and Oklahoma State University (OSU) found a “significant and noteworthy decrease” in the Alcohol Use Disorders Identification Test (AUDIT) scores of six patients who were receiving semaglutide treatment for weight loss.

Lead study author Dr. Jesse Richards, director of obesity medicine and assistant professor of medicine at the OU-TU School of Community Medicine, said the study was inspired by his conversation with Dr. Kyle Simmons, professor of pharmacology and physiology at the OSU Center for Health Sciences.

“I had been hearing from a significant number of patients that their alcohol intake was spontaneously decreasing while [they were] on the medication,” Richards told Fox News Digital.

As a bariatric surgery clinic employee, Richards noted that it’s standard to screen patients for alcohol use.

At the clinic, a number of patients tested positive for alcohol consumption, sometimes in concerning amounts.

Later, while on semaglutide medication, they reported reduced alcohol intake.

One of Richards’ patients — who previously drank large amounts of alcohol — shared a new inability to drink more than two cans of beer now because it “just doesn’t sound good.”

This response piqued Richards’ interest in learning more about patients’ aversion to alcohol, which directly correlated to his research.

Research has shown that this effect is “mediated through adjustments in the reward pathway in the brain,” he said.

“The GLP-1s are actually modifying dopamine, decreasing the craving and decreasing the motivation to acquire things in that compulsive intake category.”

The most surprising takeaway from the study, Richards said, was that the same significant treatment response was seen even at very low doses.

“We found that even patients on the lowest dose of semaglutide — a quarter milligram — had a quite significant and relatively … quick onset reduction in alcohol intake,” he said.

Of the six patients studied, all but one were on low doses — from a quarter to a half milligram.

“And that’s very encouraging because we know that the lower doses of these medications are tolerated much better,” said Richards.

While the results seem promising, the doctor said he does not recommend that patients use semaglutide treatments for alcohol use disorder at this time, due to supply and safety issues.

“If patients have [obesity and diabetes] indications for the medication and they also struggle with alcohol intake … having them on this treatment may potentially be beneficial,” Richards said.

“But because there has been a global medication shortage, and because we don’t have prospective trials and don’t know what the specific safety is versus the well-established safety data in obesity and diabetes, [I] would not recommend it just for patients who have AUD.”

There are three FDA-approved drugs available for alcoholic use disorder that are currently underused, the doctor noted.

Given that five million people in the U.S. are currently taking semaglutide medications, if it is proven that those drugs have a significant effect on alcohol use disorder, “by default, they are going to become the most widely used drug to improve these symptoms — just by virtue of the fact that so many people are on them for diabetes or obesity,” Richards noted.

He confirmed that additional research is underway with two ongoing trials.

“Since we were able to show clinically meaningful reductions in alcohol intake and AUD symptomatology in a real-world setting, that bodes very well for these types of medications,” he said.

Looking ahead, Richard said there is a need for higher-quality evidence of the medication’s impact on AUD compared to placebo drugs or environmental factors.

Even though it’s unclear whether GLP-1 producers will market the medication to AUD patients in the future, Richards said this could become an “established medical practice once the safety and efficacy has been determined.”

For patients who struggle with AUD, Richards recommended they talk to their health care providers about available treatment.

Morning Report delivers the latest news, videos, photos and more.

He also alerted patients that if they experience a reduced appetite and usually consume “a bunch of calories” in alcohol, it may be necessary to look into a more balanced diet.

Avantika Waring, 9amHealth’s chief medical officer and a trained physician and endocrinologist in San Francisco, applauded the OU and OSU study findings for further supporting what clinicians “are already seeing in practice,” she told Fox News Digital.

“GLP-1 medications have a lot of effects that we are still learning about, and the ability to decrease cravings and the reward signals related to alcohol use are just some of the benefits,” she said.

“It’s an important starting point for further clinical trials,” she added.

Waring also warned that GLP-1 medications should not be used to treat AUD specifically, as they can cause side effects such as nausea and changes in appetite.

“People struggling with alcohol use disorder should consult with their physicians before starting GLP-1 medications to make sure that they can stay hydrated and safe on therapy,” she said.

Waring noted that if ongoing clinical trials find semaglutide treatments to be effective for AUD, the medical community will “have another tool to help people living with alcohol addiction and we’ll see expanded use of these already popular drugs.”

Fox News Digital reached out to Novo Nordisk for comment on the potential link between semaglutide medications and alcohol use disorder.